Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

Today, I explain why I've taken a position in VIR, including going over its pipeline, partners, and anticipated milestones. I then look at the company's valuation and cash position as well as Seeking ...

Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.

This article first appeared on GuruFocus. Vir Biotechnology Inc (NASDAQ:VIR) is set to release its Q4 2025 earnings on Feb 23, 2026. The consensus estimate for Q4 2025 revenue is $23.18 million, and ...

VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since. A new BARDA contract to develop a COVID antibody and another drug against a ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.76 per share a year ago. These ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced strategic imperatives to focus its capital allocation on programs with the highest potential for patient impact ...

The AASLD late breaking presentation abstracts can be accessed under Events & Presentations in the Investors section of the Vir website here. Vir will host an investor conference call to discuss the ...